1-(1-甲基-1H-吲哚-5-基)-3-(吡啶-3-基)脲盐酸盐
1-(1-甲基-1H-吲哚-5-基)-3-(吡啶-3-基)脲盐酸盐
1-(1-甲基-1H-吲哚-5-基)-3-(吡啶-3-基)脲盐酸盐 性质
| 储存条件 | Inert atmosphere,Room Temperature |
|---|---|
| 溶解度 | DMSO：可溶26 mg/mL， |
| 形态 | 固体 |
| 颜色 | 淡黄色低 |
1-(1-甲基-1H-吲哚-5-基)-3-(吡啶-3-基)脲盐酸盐 用途与合成方法
|
5-HT 2B Receptor 7.5 (pKi) |
5-HT 2C Receptor 6.9 (pKi) |
5-HT 2A Receptor 5.2 (pKi) |
SB200646A (4 μM) abolishes the ethanol-induced increase in miniature inhibitory postsynaptic current (mIPSC) frequency and had no effect on basal mIPSC frequency.
SB-200646A (20 mg/kg; intravenous injection; daily; for 21 days; male albino Sprague-Dawley rats) treatment significantly decreases the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons.
The i.v. administration of 4-16 mg/kg of SB-200646A significantly increases the firing rate and % events as bursts in spontaneously active VTA dopaminergic neurons and significantly increases the % events as burst in substantia nigra pars compacta (SNC) dopaminergic neurons.
| Animal Model: | Male albino Sprague-Dawley rats (200-225 g at the beginning of treatment and 300-350 g at the time of the experiment) |
| Dosage: | 20 mg/kg |
| Administration: | Intravenous injection; daily; for 21 days |
| Result: | Significantly decreased the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons. |
1-(1-甲基-1H-吲哚-5-基)-3-(吡啶-3-基)脲盐酸盐 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-103129 | 1-(1-甲基-1H-吲哚-5-基)-3-(吡啶-3-基)脲盐酸盐 | 143797-62-0 | 5mg | 700 |
| 2024-04-30 | HY-103129 | 1-(1-甲基-1H-吲哚-5-基)-3-(吡啶-3-基)脲盐酸盐 | 143797-62-0 | 10mM * 1mLin DMSO | 770 |
